Dialysis industry news

Stories from the dialysis comunity across the globe.



Fresenius Medical Care AG Co. PT Raised to $40.00 (FMS) - sleekmoney PDF Print

Equities research analysts at RBC Capital raised their price target on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from $35.00 to $40.00 in a note issued to investors on Friday, MarketBeat Ratings reports. The brokerage currently has a “sector perform” rating on the stock. RBC Capital’s target price suggests a potential downside of 2.20% from the company’s current price.

Separately, Commerzbank AG downgraded Fresenius Medical Care AG & Co. to a “hold” rating in a research report on Friday, May 29th. Seven analysts have rated the stock with a hold rating and four have given a buy rating to the company. Fresenius Medical Care AG & Co. currently has an average rating of “Hold” and an average price target of $39.03.

Fresenius Medical Care AG & Co. (NYSE:FMS) traded down 0.34% on Friday, reaching $40.90. The company had a trading volume of 97,639 shares. The company has a 50-day moving average of $42.55 and a 200 day moving average of $41.20. The stock has a market cap of $24.86 billion and a price-to-earnings ratio of 23.66. Fresenius Medical Care AG & Co. has a one year low of $32.40 and a one year high of $44.34.

Fresenius Medical Care AG & Co. (NYSE:FMS) last announced its earnings results on Thursday, July 30th. The company reported $0.40 earnings per share for the quarter, missing the Thomson Reuters consensus estimate of $0.42 by $0.02. The company earned $4.20 billion during the quarter, compared to analysts’ expectations of $4.13 billion. The business’s revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.42 earnings per share. On average, equities research analysts predict that Fresenius Medical Care AG & Co. will post $1.76 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.image

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...

 
DaVita HealthCare Partners (DVA) Set to Announce Earnings on Tuesday - Dakota Financial News PDF Print

DaVita HealthCare Partners (NYSE:DVA) is set to post its Q215 quarterly earnings results on Tuesday, August 4th. Analysts expect DaVita HealthCare Partners to post earnings of $0.95 per share and revenue of $3.37 billion for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Tuesday, May 5th. The company reported $0.86 earnings per share (EPS) for the quarter, hitting the analysts’ consensus estimate of $0.86. During the same quarter in the prior year, the company posted $0.85 earnings per share. The company had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.25 billion. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. On average, analysts expect DaVita HealthCare Partners to post $3.77 EPS for the current fiscal year and $4.09 EPS for the next fiscal year.

DaVita HealthCare Partners (NYSE:DVA) opened at 79.03 on Friday. The company’s 50-day moving average price is $80.02 and its 200 day moving average price is $79.70. The company has a market capitalization of $16.99 billion and a price-to-earnings ratio of 39.95. DaVita HealthCare Partners has a 12 month low of $70.85 and a 12 month high of $85.17.

DVA has been the topic of several recent analyst reports. Vetr cut shares of DaVita HealthCare Partners from a “strong-buy” rating to a “buy” rating and set a $88.97 target price for the company. in a research note on Monday, July 13th. Sanford C. Bernstein reissued a “market perform” rating and issued a $80.00 price objective on shares of DaVita HealthCare Partners in a research note on Tuesday, May 12th. Piper Jaffray lifted their price target on shares of DaVita HealthCare Partners from $87.00 to $88.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Susquehanna reiterated a “neutral” rating and set a $82.00 price objective (up previously from $75.00) on shares of DaVita HealthCare Partners in a report on Saturday, May 9th. Finally, Zacks upgraded shares of DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $92.00 price target for the company in a report on Friday, May 8th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $85.44.

In other DaVita HealthCare Partners news, COO Michael David Staffieri sold 9,050 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $84.07, for a total transaction of $760,833.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Robert J. Margolis sold 31,400 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $83.39, for a total transaction of $2,618,446.00. The disclosure for this sale can be found here.

DaVita HealthCare Partners Inc. consists of two divisions, Kidney Care and HealthCare Partners (NYSE:DVA). Kidney Care is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD). Kidney Care division develops innovative clinical care, offers integrated treatment plans, personalized care teams and health-management services. As of December 31, 2014, we provided dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 173,000 patients. HealthCare Partners division is a patient- and physician-focused integrated health care delivery and management company. HealthCare Partners manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, Florida and New Mexico. As of December 2014, HealthCare Partners had approximately 837,000 members under its care.image

Receive News & Ratings for DaVita HealthCare Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners and related companies with MarketBeat.com's FREE daily email newsletter.

...

 
Exercise on dialysis: staying active to stay healthy - HealthCanal.com PDF Print

Deakin researchers have launched an Australian-first exercise program to help fight the debilitating physical side-effects suffered by patients undergoing dialysis treatment.

Dialysis and exercise_lg An Australian-first exercise program is helping fight the debilitating physical side-effects of dialysis treatment.

In partnership with Kidney Health Australia, resistance bands and exercise guides are being sent to every one of Australia's 300 dialysis treatment units at more than 100 Australian hospitals.

Deakin Professor Paul Bennett said despite almost 12,000 Australians receiving dialysis treatment for chronic kidney disease, the importance of exercise was often overlooked.

"The combination of chronic kidney disease and sitting on dialysis – for four to five hours, three times a week – causes people to deteriorate physically at an alarming rate," Professor Bennett said.

"Exercise has been shown to improve physical function, quality of life, muscle condition and the dialysis treatment in patients with kidney disease, as well as decreasing depression, cardiovascular risk and a range of other negative outcomes of kidney disease.

"Kidney-related disease kills 56 Australians every day, so it's a silent disease that not only kills but affects physical function and quality of life.

"The kits we're sending to every dialysis unit across the country will equip exercise professionals, nurses and patients with what they need to start and sustain a gentle program that will encourage patients to exercise during their dialysis treatment."

The exercise program is designed to be repeated up to three times a week at every dialysis treatment.

More information can be found on the Kidney Health Australia website.

Media contact

Katie Thompson
Media and Corporate Communications
03 9244 5256, 0418 839 638

...

 
Garma Festival 2015: Calls for more dialysis machines to treat Indigenous ... - ABC Online PDF Print

Posted August 02, 2015 10:33:57

In a room decorated with photos of kingfishers, ducks and eagles, Morgan Mununggurr has a dialysis machine named after his totem - Mana, the shark.

Three times a week he visits the Miwatj Health Clinic in Yirrkala community outside of Nhulunbuy, or about 30 minutes drive from the site of the Garma Festival, and sits in a chair hooked up to a haemodialysis blood filtering machine.

It takes about four-and-a-half hours to clean his blood. The machine clicks and whirrs and Mr Mununggurr, formerly a keen hunter, eats buttered toast and talks about the "unlucky" ones - those who have to leave their families and travel to Yirrkala or Darwin from even more remote communities.

Yirrkala has the only haemodialysis treatment outside of Darwin in the Top End of the Northern Territory - a region with the highest rate of kidney disease in the world.

Though kidney failure is the most pressing health problem affecting East Arnhem Land, at the Garma Festival it has largely been overshadowed by discussion of the Adam Goodes booing saga and the question of recognising Indigenous people in the Australian constitution.

We were homesick every day.

Malawuy Yunupingu

A panel discussion on the topic was cut short for a ceremony awarding an honorary doctorate to Gumatj clan leader Gallarwuy Yunupingu.

His elder brother Dr Yunupingu, who was the former lead singer of Yothu Yindi and remembered as a "giant among his people", died two years ago after a long battle with kidney disease.

On the panel, Dr Yunupingu's widow Malawuy Yunupingu described the "nightmare" of moving to Darwin five years ago for treatment.

At the time there were no dialysis chairs in Yirrkala.

"We were homesick every day," she said.

"That's how much we were missing home, and also missing the family."

The Yirrkala renal clinic has two machines - the one next to Mr Mununggurr is named after the totem of Dr Yunupingu - Baru, the crocodile.

Dr Yunupingu and Yalmay spearheaded the initiative to get two machines in Yirrkala. It meant he could go home and, when he died, it was on Gumatj land.

Fly in, fly out dialysis clinic suggested

Healthcare providers have advocated for more remote dialysis.

Eddie Mulholand, chief executive for local health care provider Mitwatj Health, proposed a hub-and-spoke model of treating dialysis in remote communities.

He suggested having two renal nurses in each community of north-east Arnhem Land and opening a fly in, fly out dialysis clinic out of the regional centre of Nhulunbuy.

About 1,000 people in north-east Arnhem Land have some level of kidney disease, and the rate is escalating.

Mr Mulholand estimated that without proper funding another 61 people in the region would develop end-stage kidney disease requiring similar treatment to Mr Mununggurr.

Treatment facilities are stretched to capacity. The lack of local dialysis machines means Yirrkala patients take turns travelling to Darwin for treatment, so others can receive treatment in Yirrkala.

But Mr Mulholand acknowledged more treatment was not the only answer - funding was also needed for prevention of the disease itself.

The Federal Government this week announced more than $25 million for dialysis services predominantly targeting Indigenous people living with chronic kidney disease in central Australia.

Ronald Morgan from the Kimberley region of Western Australia described how his mother donated him her kidney when he was five. It failed after 23 years of service and, seeking treatment, he moved his family 3,000 kilometres to Perth, where he struggled to find work and provide for his children.

"Even though I was sick I still had bills to pay," he said.

"I am still yet to get back to my home."

Gallery: The 2015 Garma Festival in north-east Arnhem Land

Topics: liver-and-kidneys, indigenous-policy, yirrkala-0880

More stories from Northern Territory

...

 
Dialysis urged for remote communities - Sky News Australia PDF Print

For Yalmay Yunupingu, moving to Darwin for five years so her husband, the Yothu Yindi frontman and renowned Yolngu leader Dr Yunupingu, could receive dialysis for his end-stage kidney disease was a nightmare.

Looking after her husband was no easy job, and it was compounded by the separation from their home.

"We both tried hard, looking after each other, but sometimes it was very hard ... it was a nightmare," she told a panel on renal health at the Garma Festival in Arnhem Land on Saturday.

"I was homesick nearly every day; that's how much we were missing home, and also missing the family."

Chronic kidney disease is a huge problem for Aboriginal people living in the remote Northern Territory, and many sick people choose to stay on country and not receive dialysis because they do not want to be isolated and alienated from their families, and because of cultural obligations.

The federal and NT governments this week announced more than $25 million in funding for dialysis patients in central Australia to be treated in their communities, but it remains to be seen whether there will be money for patients in the remote top end.

West Australian man Ronald Morgan had his first kidney transplant when he was five, donated by his mother.

It held out for 23 years before it failed and he had to move his family 3000 kilometres from Wyndham to Perth, disrupting his children's education and struggling to find work while he received treatment.

"The biggest thing about being sick is looking for support," he said.

Darwin-based kidney specialist Paul Lawton said he had "seen enough of the distress of Aboriginal people on dialysis, particularly the dislocation story".

Dr Lawton said a lot of the most severe cases of kidney failure could be prevented through good resourcing of primary health care services in remote communities.

Eddie Mulholand, chief executive of local health provider Miwatj Health, estimates there would be another 61 people needing dialysis in northeast Arnhem Land without proper funding.

As it stands, patients from Yirrkala are on a three weeks on, three weeks off rotation getting treatment at home and in Darwin, because of a lack of local dialysis chairs and a desire to stay close to home for as long as possible, where ties to country are very strong.

Gundumuk, a local patient, said she was happy to be able to receive at least part of her dialysis at home, which she administers herself.

"The mission is for us that we come together, Yirrkala mob, how we can get back home, because home is something we leave behind, rushing to Darwin just because of our chronic disease," she said.

"I feel really happy here at home, glad to see my family, glad to see my grandkids."

Alan Cass, of the Menzies School of Health Research, said kidney disease could fracture communities as elders get sick and are relocated together with their families.

"These are community leaders; when one person moves from Yirrkala to Darwin often a family of five goes with them," Dr Cass said.

"The impact of this disease is on the individual, on a family, on children, who have a disrupted education, on employment ... there are times when things are so intertwined we have to address health issues in order to get the outcomes we want in education, employment and community development."

AAP

...

 
<< Start < Prev 41 42 43 44 45 46 47 48 49 50 Next > End >>

Page 49 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.